ICPT Share Price

Open 66.66 Change Price %
High 67.30 1 Day 0.33 0.50
Low 65.31 1 Week 1.37 2.09
Close 66.86 1 Month -31.26 -31.86
Volume 831101 1 Year -70.99 -51.50
52 Week High 139.44
52 Week Low 54.98
ICPT Important Levels
Resistance 2 68.70
Resistance 1 67.94
Pivot 66.49
Support 1 65.78
Support 2 65.02
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
DCTH 0.04 33.33%
RITT 0.04 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
NEXS 0.05 25.00%
PRAN 3.25 24.52%
PGRX 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
LIWA 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)

ICPT Technical Analysis 5
As on 19th Oct 2017 ICPT Share Price closed @ 66.86 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 109.86 & Strong Sell for SHORT-TERM with Stoploss of 90.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
ICPT Target for October
1st Target up-side 94.52
2nd Target up-side 120.09
3rd Target up-side 145.66
1st Target down-side 21.56
2nd Target down-side -4.01
3rd Target down-side -29.58
ICPT Other Details
Segment EQ
Market Capital 330403136.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.interceptpharma.com
ICPT Address
ICPT
450 West 15th Street
New York, NY 10011
United States
Phone: 646-747-1000
Fax: 646-747-1001
ICPT Latest News
Interactive Technical Analysis Chart Intercept Pharmaceuticals, Inc. ( ICPT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Intercept Pharmaceuticals, Inc.
ICPT Business Profile
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. It is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. The Company is conducting a Phase 3 clinical trial of OCA in PBC, which it calls the POISE trial, that serves as the basis for seeking regulatory approval in the United States and Europe. As of December 19, 2012, the Company completed enrollment of the POISE trial with 217 patients.